N/A
Completed N=266
Remote Ischemic Postconditioning in Humans
Myocardial Reperfusion Injury
Source: ClinicalTrials.gov NCT01113008 ↗
Enrolled (actual)
266
Serious AEs
0.8%
Results posted
Jan 2015
Primary outcomePrimary: Maximum Increase of Troponin at 24 Hours — 0.478; 0.476 ng/ml
Summary
The aim of this study is to evaluate the phenomenon of remote ischemic post-conditioning in humans. The minor myocardial damage associated with percutaneous revascularization procedures may be attenuated by producing controlled ischemia in the arms immediately after carrying out these procedures (remote ischemic post-conditioning). The justification and design of this clinical trial has been reported: Cardiology. 2011;119(3):164-9.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximum Increase of Troponin at 24 Hours |
0.478; 0.476 | — |
| SECONDARY Readmission Due to Acute Coronary Syndrome |
1; 4 | — |
| SECONDARY Cardiovascular Mortality |
0; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Patients undergoing PCI due to stable angina
- Patients undergoing PCI due to unstable angina
- Patients undergoing PCI due NON Q acute myocardial infarction with normal troponin at inclusion moment (less than 1 ng/ml)
Exclusion Criteria
- Acute myocardial infarction during the previous two weeks
- Chronic renal failure with baseline creatinine above 3 mg/dL
- Collateral circulation of the revascularized artery (Rantrop >0) 5. Prior treatment with glibenclamide. 6. Inability to receive follow-up, blood test or lack of informed consent.
Data sourced from ClinicalTrials.gov (NCT01113008). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.